We are a biotech company focused on the discovery and development of novel, fully human monoclonal antibodies for the prevention and treatment of serious bacterial and viral infections in the hospital setting.
Michael Tamm studied medicine with a doctorate from the University of Basel. In 1991 he gained the specialist title in Internal Medicine. Michael Tamm spent a year in the United Kingdom in the Laboratory of Respiratory Physiology and Transplant Unit Papworth Hospital, Cambridge. Back in Basel he obtained the specialist title in pneumology (FMH). In 1999 Professor Tamm went to Sydney, Australia, as visiting Professor at the Institute of Respiratory Medicine. In the year 2002 he became head of the Clinic of Pneumology and Pulmonary Cell Research at the University Hospital Basel. He published more than 130 peer reviewed articles. His clinic and research laboratory are active in clinical and basic research.
Prof. Dr. med. Winfried V. Kern
Winfried Kern studied medicine in Bordeaux, Erlangen-Nürnberg and Heidelberg. Professor Kern is a specialist in Internal Medicine, Clinical Infectiology as well as Travel Medicine. His occupational career brought him to South Sudan, and the USA where he worked in San Francisco and Providence/Rhode Island.
Before he was appointed to a professorship for Internal Medicine at the University of Freiburg, he was head of the Infectiology and Clinical Immunology Unit in Ulm.
He is now head of the Infectiology Department of the University Hospital Freiburg.
Professor Kerns main research interests are infections in combination with immuno- deficiencies, mechanisms and clinical epidemiology of infections caused by multi-resistant bacteria and new rapid diagnostics tests.
Prof. Dr. Hans Hengartner
Hans Hengartner studied biochemistry and molecular biology at ETH Zurich and holds a doctorate in natural sciences from ETH Zurich. He is currently Co-Director of the Institute for Experimental Immunology at the University Hospital of Zurich. He is also ordinary professor for immunology at the medical faculty of the University of Zurich and at the Department of biology of ETH Zurich. From 2000 to 2005 Hans Hengartner was Head of the Department of Biology at ETH Zurich.
Prof. Dr. med. , Dr. rer. nat. Jürgen Heesemann
Jürgen Heesemann studied chemistry at the University of Hamburg and Human Medicine at the University of Göttingen. He gained his doctorate as Dr. rer. nat. in the Faculty of Physical Chemistry and his Dr. med. qualification in the Faculty of Electrophysiology at the University of Göttingen. He is currently Professor of Bacteriology and Director of the Max von Pettenkofer Institute for Hygiene and Medical Microbiology at the University of Munich. He is also a member of the Council of the Centre for Infection Research at the University of Würz-burg, Chairman of the Committee of the Programme for the Promotion of Research and Teaching (Förderprogramm für Forschung und Lehre [FöFoLe]) of the Medical Faculty of the Ludwig Maximilians University, Munich (since 1999) and President of the German Society for Hygiene and Microbiology (Deutsche Gesellschaft für Hygiene und Mikrobiologie [DGHM]).
Jürgen Heesemann has received a number of awards, including the Dr. Martini Prize Ham-burg, the Special Prize of the Robert Koch Foundation, the Main Prize of the DGHM Foundation and the Aronson Prize of the City of Berlin.
Prof. Peter JM Openshaw
Peter JM Openshaw was trained in Medicine at Guy’s Hospital and was awarded the Treasurer’s Gold Medal in Medicine. After SHO (Brompton, Turner-Warwick; Guy’s, Renal), and registrar posts (Hammersmith Hospital and Ealing), he became senior registrar then consultant physician at St Mary’s Hospital, Paddington.
He founded the Academic Department of Respiratory Medicine at the St Mary's Campus of Imperial College in 1988, which he now leads. He is also Head of the Respiratory Infections Section of the National Heart and Lung Institute, a Division of the Faculty of Medicine of Imperial College London. The department is dedicated to the research on the immunopathogenesis of pulmonary viral infection and obstructive lung disease. His work is funded by the Wellcome Trust and Medical Research Council, UK.
He teaches undergraduates and postgraduate students, lecturing on immunology, vaccination and lung diseases. He organised and chaired the RSV symposium (Oxford, September 2005), a biennial global conference of ~250 experts. He reviews regularly for Nature Medicine, Nature Immunology, Journal of Experimental Medicine, The Lancet, Vaccine, Journal of Immunology, Journal of Virology etc. He is a member of the Council of the British Society for Immunology and of the Wellcome Trust’s Tropical and Clinical funding committee. He was elected a Fellow of the Academy of Medical Sciences in 1999.
